Brooks Automation Reports Results of First Quarter of Fiscal 2020, Ended December 31, 2019, and Announces Quarterly Cash Dividend
CHELMSFORD, Mass., Feb. 6, 2020 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS), a leader in automation solutions for the semiconductor manufacturing and life sciences industries, today reported financial results for the first fiscal quarter of 2020, ended December 31, 2019.
Financial Results Summary
Quarter Ended
Dollars in millions, except per share data December 31, September 30, December 31, Change vs.
2019 2019 2018 Prior Qtr Prior Year
Revenue $
210 $
199 $
179 6
% 17
%
Semiconductor Solutions Group $
119 $
105 $
113 13
% 5
%
Life Sciences $
92 $
94 $
67 (3)
% 38
%
Diluted EPS Continuing Operations $
0.18 $
0.07 $
0.09 150
% 106
%
Diluted EPS Total $
0.18 $
5.68 $
0.20 (97) (11)
% %
Non-GAAP Diluted EPS Cont. Operations $
0.23 $
0.23 $
0.17 (3)
% 37
%
Management Comments
"The results of our first fiscal quarter of 2020 showed good growth in each segment and we are solidly on track for a strong year," commented Steve Schwartz, CEO of Brooks Automation. "Our Semiconductor Solutions business was lifted by another record quarter of revenue from Contamination Control Solutions, we delivered another quarter of gross margin improvement in Life Sciences Sample Management, and we had strong cash flow from operations."
Summary of GAAP Results for Continuing Operations
-- Revenue of $210 million grew 17% year-over-year and diluted EPS from
continuing operations was $0.18, which has doubled from $0.09 in the
first quarter of 2019.
-- Life Sciences revenue of $92 million grew 38% year-over-year, helped by
the acquisition and continued growth of GENEWIZ, which was acquired on
November 15, 2018. The organic growth of GENEWIZ was 22% and for Sample
Management 3%, year-over-year.
-- Semiconductor Solutions revenue of $119 million grew 5% year-over-year
and 13% sequentially, driven by strong shipments of Contamination
Control Solutions to end-user fabs and vacuum robots to OEM customers.
-- GAAP operating income was $11 million, compared to $5 million in the
first quarter of 2019. The increase was driven by the growth and
expanded operating margins in Life Sciences. Life Sciences margins
benefited from 340 basis points expansion of gross margins in Sample
Management and improved mix from a full quarter of the higher margin
results of GENEWIZ compared to a half quarter a year ago.
-- Amortization of intangibles was $11 million, an increase of
approximately $3 million due to carrying GENEWIZ for a full quarter in
2020 versus a half quarter of ownership in the first fiscal quarter of
2019.
-- Net interest expense was zero for the quarter, a $5 million reduction
from the first quarter of 2019.
-- Cash flow from operations was $26 million in the quarter, compared to $6
million in the first quarter of 2019. The ending balance of total debt
was $51 million and the balance of cash, cash equivalents, restricted
cash, and marketable securities was $353 million. In January 2020,
subsequent to the first quarter reporting period, the Company used $93
million of this cash balance to settle income taxes related to the 2019
gain on the sale of the Semiconductor Cryogenics business.
Summary of Non-GAAP Results for Continuing Operations
-- Diluted EPS from continuing operations for the quarter was $0.23, up 37%
from the first quarter of 2019.
-- Operating margins were 10.5%, down 50 basis points year-over-year. The
current quarter includes higher SG&A expense driven primarily by the
additional structure acquired with GENEWIZ and subsequent investments
for its growth. The first fiscal quarter included excess professional
fees of approximately $2 million, primarily associated with the
previously disclosed material weaknesses that impacted operating margins
negatively by approximately 100 basis points.
-- Non-GAAP gross margins were 41.6%, an increase of 20 basis points from
the first quarter of 2019 driven by improved margins in Life Sciences,
partially offset by lower margins in Semiconductor.
-- Life Sciences non-GAAP operating margins were 6.5%, up 250 basis points
year-over-year. The improvement was primarily driven at the gross margin
line which was 44.3%, up 350 basis points year-over-year. This reflects
340 basis point improvement in Sample Management gross margins and the
favorable mix of acquiring the GENEWIZ business which carries higher
gross margins.
-- The Semiconductor Solutions non-GAAP operating margins were 12.6%, a
decline of 270 basis points. The decline reflects softer gross margins
of 39.6%, lower by 210 basis points from the prior year, primarily
driven by the mix of revenue.
-- Adjusted EBITDA was $32 million, up 14% from the first quarter of 2019.
A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures follows the consolidated balance sheets, statements of operations and statements of cash flows included in this release.
Quarterly Cash Dividend
The Company additionally announced that the Board of Directors has reiterated a dividend of $0.10 per share payable on March 27, 2020 to stockholders of record on March 6, 2020. Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors.
Guidance for Fiscal Second Quarter Fiscal 2020
The Company announced revenue and earnings guidance for the second quarter of fiscal 2020. Revenue is expected to be in the range of $213 million to $225 million and non-GAAP diluted earnings per share is expected to be in the range of $0.22 to $0.28. GAAP diluted earnings per share for the second fiscal quarter is expected to be in the range of $0.09 to $0.15.
Conference Call
Brooks management will webcast its first quarter earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.
The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Brooks' website at www.brooks.com, and will be archived online on this website for convenient on-demand replay. In addition, you may call 800-728-2056 (US & Canada only) or +1-212-231-2922 for international callers to listen to the live webcast.
Regulation G - Use of Non-GAAP financial Measures
The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analysis provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets, statements of operations and statements of cash flows.
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include but are not limited to statements our revenue and earnings expectations, our ability to increase our profitability, our ability to improve or retain our market position, and our ability to deliver financial success in the future. Factors that could cause results to differ from our expectations include the following: the volatility of the industries the Company serves, particularly the semiconductor industry; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; risks and uncertainties related to the coronavirus originating in Wuhan, China and its effects on the Company's operations in China, including supply chain, and the operations of our customers in China; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release.
About Brooks Automation, Inc.
Brooks is a leading provider of life science and semiconductor manufacturing automation solutions worldwide. The Company applies its automation and cryogenics expertise to provide a full suite of reliable cold-chain sample management solutions across life sciences in areas such as drug development, clinical research and advanced cell therapies. Brooks recently added global capability for gene sequencing and gene synthesis services through its strategic acquisition of GENEWIZ, expanding its sample-based services offerings. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks is a provider of industry-leading precision robotics, integrated automation systems and services. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit www.brooks.com.
INVESTOR CONTACTS:
Mark Namaroff
Director, Investor Relations
Brooks Automation
978.262.2635
mark.namaroff@brooks.com
Sherry Dinsmore
Brooks Automation
978.262.2400
sherry.dinsmore@brooks.com
John Mills
Senior Managing Partner
ICR, LLC
646.277.1254
john.mills@icrinc.com
BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except per share data)
Three Months Ended
December 31,
2019 2018
Revenue
Products $
131,862 $
125,375
Services 78,638 53,993
Total revenue 210,500 179,368
Cost of revenue
Products 79,971 74,574
Services 45,543 32,713
Total cost of revenue 125,514 107,287
Gross profit 84,986 72,081
Operating expenses
Research and development 14,401 13,148
Selling, general and administrative 59,343 53,541
Restructuring charges 576 59
Total operating expenses 74,320 66,748
Operating income 10,666 5,333
Interest income 699 423
Interest expense (737) (5,290)
Other expenses, net (417) (30)
Income before income taxes 10,211 436
Income tax benefit (2,963) (5,830)
Income from continuing operations 13,174 6,266
(Loss) income from discontinued operations, net of tax (117) 8,149
Net income $
13,057 $
14,415
Basic net income per share:
---
Basic net income per share from continuing operations $
0.18 $
0.09
Basic net (loss) income per share from discontinued operations (0.00) 0.11
Basic net income per share $
0.18 $
0.20
Diluted net income per share:
---
Diluted net income per share from continuing operations $
0.18 $
0.09
Diluted net (loss) income per share from discontinued operations (0.00) 0.11
Diluted net income per share $
0.18 $
0.20
Weighted average shares outstanding used in computing net income per share:
Basic 72,972 71,450
Diluted 73,645 72,165
BROOKS AUTOMATION, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except share and per share data)
December 31, September 30,
2019 2019
---
Assets
Current assets
Cash and cash equivalents $
335,319 $
301,642
Marketable securities 11,233 34,124
Accounts receivable, net 165,176 165,602
Inventories 105,181 99,445
Prepaid expenses and other current assets 46,560 46,332
Total current assets 663,469 647,145
Property, plant and equipment, net 105,296 100,669
Long-term marketable securities 3,039 2,845
Long-term deferred tax assets 6,004 5,064
Goodwill 490,370 488,602
Intangible assets, net 242,248 251,168
Other assets 48,532 20,506
Total assets $
1,558,958 $
1,515,999
===
Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt $
827 $
829
Accounts payable 65,306 58,919
Deferred revenue 29,042 29,435
Accrued warranty and retrofit costs 7,493 7,175
Accrued compensation and benefits 25,810 31,375
Accrued restructuring costs 844 1,040
Accrued income taxes payable 100,451 99,263
Accrued expenses and other current liabilities 53,179 44,234
Total current liabilities 282,952 272,270
Long-term debt 49,918 50,315
Long-term tax reserves 18,543 18,274
Long-term deferred tax liabilities 13,636 20,636
Long-term pension liabilities 5,397 5,338
Long-term operating lease liabilities 20,526
Other long-term liabilities 9,291 10,212
Total liabilities 400,263 377,045
Stockholders' Equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value -125,000,000 shares authorized, 87,080,017 shares issued and 73,618,148
shares outstanding at December 31, 2019, 85,759,700 shares issued and 72,297,831 shares outstanding at
September 30, 2019 871 857
Additional paid-in capital 1,926,350 1,921,954
Accumulated other comprehensive income 13,154 3,511
Treasury stock at cost - 13,461,869 shares (200,956) (200,956)
Accumulated deficit (580,724) (586,412)
Total stockholders' equity 1,158,695 1,138,954
Total liabilities and stockholders' equity $
1,558,958 $
1,515,999
===
BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
Three Months Ended
December 31,
2019 2018
---
Cash flows from operating activities
Net income $
13,057 $
14,415
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization 16,477 11,838
Stock-based compensation 4,410 4,467
Amortization of premium on marketable securities and
deferred financing costs 67 235
Earnings of equity method investments (1,772)
Deferred income taxes (8,183) (7,682)
Other gains on disposals of assets 126 6
Loss on sale of divestiture, net of tax 319
Changes in operating assets and liabilities, net of
acquisitions:
Accounts receivable 1,503 (13,826)
Inventories (4,335) (12,260)
Prepaid expenses and current assets 6,120 1,029
Accounts payable 5,255 7,932
Deferred revenue (720) 6,385
Accrued warranty and retrofit costs 221 572
Accrued compensation and tax withholdings (5,755) (13,842)
Accrued restructuring costs (203) (181)
Accrued expenses and current liabilities (2,616) 8,948
Net cash provided by operating activities 25,743 6,264
Cash flows from investing activities
Purchases of property, plant and equipment (9,614) (3,560)
Purchases of marketable securities (10,742) (1,290)
Sales of marketable securities 48,904
Maturities of marketable securities 33,584 2,557
Acquisitions, net of cash acquired (445,210)
Net cash provided by (used) in investing activities 13,228 (398,599)
Cash flows from financing activities
Proceeds from term loans, net of discount 340,540
Principal payments on debt (414) (1,789)
Payments of capital leases (319) (121)
Common stock dividends paid (7,369) (7,208)
Net cash provided by (used in) financing activities (8,102) 331,422
Effects of exchange rate changes on cash and cash
equivalents 2,808 (1,004)
Net increase (decrease) in cash and cash equivalents 33,677 (61,917)
Cash and cash equivalents and restricted cash, beginning
of period 305,171 197,708
Cash and cash equivalents and restricted cash,
end of period $
338,848 $
135,791
===
Reconciliation of cash, cash equivalents, and restricted
cash to the consolidated balance sheets
Cash and cash equivalents $
335,319 $
135,741
Restricted cash included in prepaid expenses and other
current assets 3,529 50
Total cash, cash equivalents and restricted
cash shown in the consolidated statements of
cash flows $
338,848 $
135,791
===
Notes on Non-GAAP Financial Measures:
These financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusted the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, as well as other gains and charges that are not representative of the normal operations of the business. In this context, the Company has also removed the effect of reversing the valuation allowance reserve on the U.S. deferred income tax assets. Management strongly encourages investors to review our financial statements and publicly-filed reports in their entirety and not rely on any single measure.
Quarter Ended
December 31, 2019 September 30, 2019 December 31, 2018
per diluted per diluted per diluted
Dollars in thousands, except per share data share share share
Net income from continuing operations $
13,174 $
0.18 $
5,195 $
0.07 $
6,266 $
0.09
Adjustments:
---
Purchase accounting impact on inventory and contracts acquired 184 0.00
Amortization of intangible assets 10,584 0.14 8,931 0.12 7,776 0.11
Restructuring charges 576 0.01 1,209 0.02 59 0.00
Loss on extinguishment of debt 5,288 0.07
Merger costs 195 0.00 134 0.00 6,354 0.09
Restructuring related charges 285 0.00
Adjustment of valuation allowance against deferred tax assets (233) (0.00)
Tax Reform (1) (1,125) (0.02)
Tax adjustments (2) (5,230) (0.07) (4,411) (0.06)
Tax effect of adjustments (2,662) (0.04) (3,932) (0.05) (3,184) (0.04)
Non-GAAP adjusted net income from continuing operations $
16,637 $
0.23 $
16,877 $
0.23 $
11,919 $
0.17
Stock based compensation, pre-tax 4,410 0.06 4,941 0.07 4,176 0.06
Tax rate 15 15 15
% % %
Stock-based compensation, net of tax 3,749 0.05 4,200 0.06 3,550 0.05
Non-GAAP adjusted net income excluding stock-based compensation - continuing
operations $
20,386 $
0.28 $
21,077 $
0.29 $
15,469 $
0.21
Shares used in computing non-GAAP diluted net income per share 73,645 72,558 72,165
(1) Adjustments are related to U.S.
Federal Tax Reform Transition Tax.
(2) The Company elected to apply the
tax benefit related to the stock
compensation windfall realized in
the quarters ended December 31,
2019 and 2018 to the non-GAAP
full year tax rate. The Company
elected to exclude a deferred tax
benefit realized in the three
month period ended December 31,
2019 related to the extension of
the 15 percent tax rate incentive
in China and a deferred tax
benefit realized in the three
month period ended December 31,
2018 related to a change in the
Company's state effective tax rate
driven by the acquisition of
GENEWIZ.
Quarter Ended
December 31, September 30, December 31,
Dollars in thousands 2019 2019 2018
GAAP net income $
13,057 $
412,326 $
14,415
Adjustments:
---
Less: Loss (income) from
discontinued operations 117 (407,131) (8,149)
Less: Interest income (699) (602) (423)
Add: Interest expense 737 902 5,290
Add: Income tax benefit (2,963) (511) (5,830)
Add: Depreciation 5,891 5,094 4,060
Add: Amortization of completed
technology 2,674 2,764 2,007
Add: Amortization of customer
relationships and acquired
intangible assets 7,910 6,167 5,769
Add: Loss on extinguishment of
debt 5,288
Earnings before interest, taxes,
depreciation and amortization $
26,724 $
24,297 $
17,139
Quarter Ended
December 31, September 30, December 31,
Dollars in thousands 2019 2019 2018
Earnings before interest, taxes,
depreciation and amortization $
26,726 $
24,297 $
17,139
Adjustments:
---
Add: Stock-based compensation 4,410 4,941 4,176
Add: Restructuring charges 576 1,209 59
Add: Restructuring related charges 285
Add: Purchase accounting impact on
inventory and contracts acquired 184
Add: Merger costs 195 134 6,354
Adjusted earnings before interest,
taxes, depreciation and
amortization $
31,907 $
30,866 $
27,912
Quarter Ended
---
Dollars in thousands December 31, 2019 September 30, 2019 December 31, 2018
GAAP gross profit/margin $
84,986 40.4 $
80,153 40.2 $
72,081 40.2
percentage
% % %
Adjustments:
---
Amortization of completed
technology 2,674 1.3 2,764 1.4 2,007 1.1
Restructuring related charges 285 0.1
Purchase accounting impact on
inventory and contracts acquired 184 0.1
Non-GAAP adjusted gross profit/ $
87,660 41.6 $
83,202 41.8 $
74,272 41.4
gross margin percentage
% % %
Brooks Semiconductor Solutions Group
---
Quarter Ended
Dollars in thousands December 31, 2019 September 30, 2019 December 31, 2018
GAAP gross profit/margin $
46,300 39.0 $
42,262 40.2 $
45,915 40.7
percentage
% % %
Adjustments:
---
Amortization of completed
technology 732 0.6 868 0.8 937 0.8
Purchase accounting impact on
inventory and contracts acquired 184 0.2
Non-GAAP adjusted gross profit/ $
47,032 39.6 $
43,130 41.1 $
47,036 41.7
margin percentage
% % %
Brooks Life Sciences
---
Quarter Ended
Dollars in thousands December 31, 2019 September 30, 2019 December 31, 2018
GAAP gross profit/margin $
38,686 42.2 $
37,891 40.2 $
26,166 39.3
percentage
% % %
Adjustments:
---
Amortization of completed
technology 1,942 2.1 1,896 2.0 1,070 1.6
Restructuring related charges 285 0.3
Non-GAAP adjusted gross profit/ $
40,628 44.3 $
40,072 42.6 $
27,236 40.9
margin percentage
% % %
Brooks Semiconductor Solutions Group
Brooks Life Sciences
Total Segments
--- --- ---
Quarter Ended
Quarter Ended
Quarter Ended
December 31, September 30, December 31, December 31, September 30, December 31, December 31, September 30, December 31,
Dollars in thousands 2019 2019 2018 2019 2019 2018 2019 2019 2018
GAAP operating profit $
14,268 $
12,726 $
16,141 $
4,032 $
4,586 $
1,590 $
18,300 $
17,312 $
17,731
Adjustments:
---
Amortization of completed technology 732 868 937 1,942 1,896 1,070 2,674 2,764 2,007
Purchase accounting impact on
inventory and contracts acquired 184 184
Restructuring related charges 285 285
Non-GAAP adjusted operating profit $
15,000 $
13,594 $
17,262 $
5,974 $
6,767 $
2,660 $
20,974 $
20,361 $
19,922
Total Segments
Corporate
Total
--- --- ---
Quarter Ended
Quarter Ended
Quarter Ended
December 31, September 30, December 31, December 31, September 30, December 31, December 31, September 30, December 31,
Dollars in thousands 2019 2019 2018 2019 2019 2018 2019 2019 2018
GAAP operating profit (loss) $
18,300 $
17,312 $
17,731 $
(7,634) $
(6,702) $
(12,398) $
10,666 $
10,610 $
5,333
Adjustments:
---
Amortization of completed technology 2,674 2,764 2,007 2,674 2,764 2,007
Amortization of customer relationships and
acquired intangible assets 7,910 6,167 5,769 7,910 6,167 5,769
Restructuring charges 576 1,209 59 576 1,209 59
Purchase accounting impact on inventory and
contracts acquired 184 184
Merger costs 195 134 6,354 195 134 6,354
Restructuring related charges 285 285
Non-GAAP adjusted operating profit (loss) $
20,974 $
20,361 $
19,922 $
1,047 $
808 $
(216) $
22,021 $
21,169 $
19,706
View original content to download multimedia:http://www.prnewswire.com/news-releases/brooks-automation-reports-results-of-first-quarter-of-fiscal-2020-ended-december-31-2019-and-announces-quarterly-cash-dividend-301000618.html
SOURCE Brooks Automation
